Literature DB >> 10606776

Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate.

Y Kobayashi1, S Ito, S Itai, K Yamamoto.   

Abstract

The dissolution behaviors of carbamazepine (CZP) polymorphs and pseudopolymorphs (form I, form III and dihydrate) and the bioavailabilities (BA) of each form in dogs after oral administration were investigated. Bioavailability tests were carried out at a dose of either 40 mg/body or 200 mg/body. The results of dissolution tests in JP13 first fluid (pH 1.2) at 37 degrees C indicated that the initial dissolution rate was in the order of form III>form I>dihydrate, while form III was transformed to dihydrate more rapidly than form I, resulting in decrease of the dissolution rate. The solubilities of both anhydrates (form I and form III), calculated from the initial dissolution rate of each anhydrate, were 1.5--1.6 times that of the dihydrate. At the dose of 40 mg/body, there were no significant differences in the area under the curve (AUC) between forms; their AUCs were nearly equal to that of CZP solution using polyethyleneglycol 400. These findings suggested that most crystalline powder of each form administered at the low dose was rapidly dissolved in gastrointestinal (GI) fluid. On the other hand, for the dose of 200 mg/body, significant differences in plasma concentration--time curves of CZP among polymorphic forms and dihydrate were observed. The order of AUC values was form I>form III>dihydrate. The inconsistency between the order of initial dissolution rates and that of AUC values at the high dose may have been due to rapid transformation from form III to dihydrate in GI fluids.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10606776     DOI: 10.1016/s0378-5173(99)00315-4

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  24 in total

1.  Parallel thermal analysis technology using an infrared camera for high-throughput evaluation of active pharmaceutical ingredients: a case study of melting point determination.

Authors:  Kohsaku Kawakami
Journal:  AAPS PharmSciTech       Date:  2010-07-31       Impact factor: 3.246

2.  Influence of temperature on solvent-mediated anhydrate-to-hydrate transformation kinetics.

Authors:  Haiyan Qu; Tommy Munk; Claus Cornett; Jian X Wu; Johan P Bøtker; Lars P Christensen; Jukka Rantanen; Fang Tian
Journal:  Pharm Res       Date:  2010-10-01       Impact factor: 4.200

3.  Dehydration kinetics and crystal water dynamics of carbamazepine dihydrate.

Authors:  K Kachrimanis; U J Griesser
Journal:  Pharm Res       Date:  2012-04       Impact factor: 4.200

4.  One ring to dissolve them all.

Authors:  Jonathan J Halford
Journal:  Epilepsy Curr       Date:  2015 Jan-Feb       Impact factor: 7.500

Review 5.  Role of solvents in improvement of dissolution rate of drugs: crystal habit and crystal agglomeration.

Authors:  Maryam Maghsoodi
Journal:  Adv Pharm Bull       Date:  2015-03-05

6.  Close intramolecular sulfur-oxygen contacts: modified force field parameters for improved conformation generation.

Authors:  Dmitry Lupyan; Yuriy A Abramov; Woody Sherman
Journal:  J Comput Aided Mol Des       Date:  2012-10-06       Impact factor: 3.686

7.  Improving Dissolution Rate of Carbamazepine-Glutaric Acid Cocrystal Through Solubilization by Excess Coformer.

Authors:  Hiroyuki Yamashita; Changquan Calvin Sun
Journal:  Pharm Res       Date:  2017-12-29       Impact factor: 4.200

8.  A New Extrudable Form of Hypromellose: AFFINISOL™ HPMC HME.

Authors:  Siyuan Huang; Kevin P O'Donnell; Justin M Keen; Mark A Rickard; James W McGinity; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2015-09-04       Impact factor: 3.246

9.  Dissolution behavior of a poorly water soluble compound in the presence of Tween 80.

Authors:  Linna R Chen; James A Wesley; Shobha Bhattachar; Bienvenido Ruiz; Korey Bahash; Suresh R Babu
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

10.  Development of a mini-tablet of co-grinded prednisone-Neusilin complex for pediatric use.

Authors:  H Lou; M Liu; L Wang; S R Mishra; W Qu; J Johnson; E Brunson; H Almoazen
Journal:  AAPS PharmSciTech       Date:  2013-06-13       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.